Chinese conglomerate Fosun International will buy the remaining stake in Shanghai Henlius Biotech it does not already own in a deal that values the Hong Kong-listed drugmaker at HK$13.37 billion ($1.71 billion), the companies said on Monday.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
